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Isolated superficial inguinal metastases without any extended intra-abdominal spread is a rare event in patients with
ovarian carcinoma. Here we report an isolated superficial inguinal metastasis in a patient with primary ovarian
cancer. A 54-year-old Chinese patient with primary ovarian cancer, had an isolated painless enlarged right groin
swelling (3×2cm) as the only manifestation, preoperative pathology confirmed metastatic adenocarcinoma.
Gynecologic examination, transvaginal ultrasonography of the abdominopelvic cavity revealed a 5-cm mixed, right
adnexal mass. At exploratory laparotomy, there was little intra-abdominal tumor dissemination but 100 ml of faint
yellow peritoneal fluid and a 5-cm right ovarian tumor with intact capsule. Staging operation was performed and
postoperative pathology confirmed adenocarcinoma located within right ovarian, with no evidence of
involvement of other sites. Then the patient received adjuvant chemotherapy for Stage IVB. Five years later, the
patient is currently still alive without evidence of recurrent disease. This case indicate that ovarian carcinoma isn’t a
disease localized only within the intra-peritoneal cavity, isolated superficial inguinal lymph node metastasis might
occur in rare cases via potential lymphatic and (or) hematogenous route under special conditions. We propose the
need to investigate the possible mechanisms, risk factors, metastatic patterns, the biology and natural history of
such patients in a large-scale and multicenter analysis. Furthermore, efforts should be made for earlier and
differential diagnosis and finally prolong survival time for such patients.
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Ovarian carcinoma is the most frequent cause of death
from gynecological malignancies in China [1]. The main
reason of its high mortality is due to the lack of symptoms
for early detecting. Over 70% of patients with ovarian car-
cinoma were diagnosed as International Federation of
Gynecology and Obstetrics (FIGO) stage III or IV at their
initial presentation [2]. The most frequent symptoms in-
clude abdominal pain, distension, early satiety, vaginal
bleeding or a combination of these, and the most common
sign present at initial visit is a pelvic mass [3]. Patients
with ovarian cancer were reported to presented with* Correspondence: ourongying@163.com
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unless otherwise stated.distant metastatic deposits in the cervix, vagina, or vulva
at their initial visit [4]. Lymph node metastasis occurred in
about 14-70% of patients with ovarian carcinoma and dis-
tributed mainly in the pelvic and aortic region [5]. Never-
theless, it is uncommon to present superficial inguinal
lymph node (SILN) metastasis in patients with early stage
of ovarian carcinoma. Isolated SILN metastasis was a very
rare event in patients with ovarian carcinoma [6]. Here we
report a 54-year-old patient with complete clinicopatho-
logical data, who attacked by occult primary ovarian can-
cer limited within the right ovary, while initially presented
with an asymptomatic isolated enlarged right SILN and
confirmed to be a metastatic adenocarcinoma by pre-
operative pathological examination. Its potential implica-
tions in basic science research and clinical management
are discussed.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Preoperative pathologic diagnosis by fine needle
aspiration demonstrated a metastatic adenocarcinoma within
right SILN (haematoxylin and eosin stain; original
magnification, ×50).
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In June 2008, a 54-year-old Chinese woman, postmeno-
pausal for 8 years, presented to our hospital with com-
plaints of an isolated painless enlarged mass at right
groin. On gross inspection, a palpable painless enlarged
subcutaneous swelling (3 × 2 cm) were observed within
the right groin. The contralateral inguinal nodes and the
scalene nodes were clinically negative. Gynecologic
examination showed a 5 cm fixed mass within the right
adnexa. Transvaginal ultrasonography (TVUSG) showed
a 5 × 4 × 5 cm mixed lump within the right adnexa, has
relatively rich blood supply signals on the circumference
and inside tumor, with papillary vegetation and irregular
septa, together with a small amount of pelvic fluid
(Figure 1). Results of endometrial and cervical biopsies,
thyroid sonography, gastroduodenoscopy, colonoscopy,
were all negative. Serum tumor markers including
CA125 were all within normal range. Systematic infec-
tious disease that can cause enlarged inguinal lymph
node were analyzed, including hepatitis A, hepatitis B,
hepatitis C, syphilis, HIV, HSV, and the results were all
negative. No ulcers were presented in the lower genital
tract. Patient was also screen for potential presence of
Trichomonas vaginalis, genital Chlamydia trachomatis,
and Neisseria gonorrhoeae, and results were all negative.
Five days later, the patient received fine needle aspiration
for the right groin swelling and preoperative pathological
examination confirmed a metastatic adenocarcinoma
(Figure 2).
Eleven days later, exploratory laparotomy were per-
formed, there was little intra-abdominal tumorFigure 1 Preoperative transvaginal ultrasonography (TVUSG) showed
relatively rich blood supply signals on the circumference and inside tumor,
amount of pelvic fluid.dissemination but 100 ml of faint yellow peritoneal fluid
and a 5-cm right ovarian tumor with intact capsule, the
rest of abdominopelvic cavity remained macroscopically
negative. During the surgery, frozen sections for right ad-
nexal mass revealed a low-grade differentiated serous
ovarian papilliferous cystadenocarcinoma. According to
procedures of staging operation for ovarian carcinoma
[2], total abdominal hysterectomy, bilateral salpingo-
ovariectomy, complete removal of the omentum, append-
ectomy, random biopsies of the peritoneum, systematic
pelvic and paraaortic lymphadenectomy were performed,a 5 × 4 × 5 cm mixed lump within the right adnexa. It has
with papillary vegetation and irregular septa, together with a small
Figure 4 Postoperative pathologic diagnosis show poorly
differentiated serous cystadenocarcinoma within SILN
metastases from ovarian cancer. There were psammoma bodies
in tumor stroma, consistent with preoperative fine needle aspiration.
(haematoxylin and eosin stain; original magnification, ×100).
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Postoperative pathologic diagnosis showed a poorly
differentiated serous papilliferous cystadenocarcinoma of
the right ovary (Figure 3), and right inguinal lymph node
metastasis (Figure 4), which consistent with preoperative
fine needle aspiration, immunohistochemical staining
showed positive cytoplasmic CA125 expression both in
ovarian cancer tissues (Figure 5) and in metastatic SILN
(Figure 6), cytology of the pelvic fluid showed poor dif-
ferentiated adenocarcinoma cells (FIGO G3). The rest of
pathological diagnosis showed no evidence of dissemi-
nated intraperitoneal and retroperitoneal metastatic
disease, all pelvic and paraaortic lymph nodes were
negative (Figure 7). The patient was diagnosed to be
FIGO Stage IVB [7] and then referred to postoperative
adjuvant chemotherapy with paclitaxel (175 mg/m2) and
carboplatin (AUC-5) at 28-day intervals for six cycles.
Chemotherapy was completed in January 2009. Pres-
ently, five years after the primary diagnosis, this patient
is still alive with no evidence of recurrent disease.
Discussion
Incidence of inguinal lymph node metastasis
Lymph node metastases can be well recognized in ovar-
ian cancer with sampling of retroperitoneal lymph nodes
as an integral part of the staging operation [8]. FIGO in-
troduced inguinal lymph node involvement into the def-
inition of stage IVB in ovarian carcinoma since 2013 [7],
while patients exhibited metastatic retroperitoneal
lymph nodes are classified as stage IIIC even when the
primary tumor is limited to the pelvis [9]. The most
common way of spreading in ovarian carcinoma is
lymphatic metastasis and transcoelomic spread to adja-
cent viscera, with distant metastasis often concurringFigure 3 Postoperative pathologic diagnosis confirmed poorly
differentiated serous papilliferous cystadenocarcinoma of the
right ovary (FIGO G3). Cancer cells were arranged to form irregular
solid and reticular structures. (haematoxylin and eosin stain; original
magnification, ×50).with extensive intra-abdominal dissemination [10].
Nevertheless, isolated SILN involvement in patients
without any extended intraabdominal spread is a rare
event [6,11,12].
The incidence of inguinal lymph node metastasis in
ovarian carcinoma was approximately 3-5% as reported
in literatures [6,11,13,14], while these studies can't pro-
vide enough clinical informations and pathological fea-
tures. A little bit more detailed descriptions include
following cases. A patient presenting with an enlarged
inguinal lymph node, was finally diagnosed to be endo-
metrioid carcinoma of the ovary [15]; a patient presented
with metastatic inguinal lymphadenopathy was con-
firmed with poorly differentiated ovarian malignancy
until 33 months later [16]; an eighteen-year old female
patient complained with enlarged inguinal lymph nodesFigure 5 Postoperative positive cytoplasmic immunostaining of
CA125 was detected in primary ovarian cancer tissues (CA125
receptor stain; original magnification: ×100).
Figure 6 Postoperative positive cytoplasmic immunostaining of
CA125 was detected in SILN metastases from ovarian cancer
(CA125 receptor stain; original magnification: ×100).
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tumors (approximately 6 cm diameter) detected by com-
puted tomography, and was finally proved to be stromal
infiltration of signet-ring cell carcinoma in both ovaries
[17]; a 48-year-old patient presented with 6-month his-
tory of inguinal swelling, was confirmed with a serous
papillary ovarian carcinoma, thus indicated that inguinal
lymphadenopathy can be initial symptom epithelial ovar-
ian carcinoma [18]. Nevertheless, these studies were also
inconclusive, since they neglected to give any further de-
tailed information on pathological examination of the
pelvic and paraaortic lymph nodes, and whether inguinal
lymph node metastasis occurred in isolation or con-
curred with other sites of neoplasm metastasis.
To the best of our knowledge, the following three re-
cords provided full clinicopathological features in this
regards. Scholz et al. [19] firstly reported a patient withFigure 7 Histological features of non-metastatic pelvic and
paraaortic lymph nodes from ovarian cancer (haematoxylin and
eosin stain; original magnification: ×100). Present with
lymphonode reactive hyperplasia and without tumor cells invasion.undifferentiated serous adenocarcinoma of both ovaries
(10 × 5.5 cm), and involvement of fimbria of the right
fallopian tube, and positive peritoneal washing, initially
displayed an isolated left inguinal node metastasis, with-
out other nodal groups involvement. Then Manci et al.
[20] reported that, a patient complained with bilateral
inguinal lymphadenopathy, showed an increased uptake
of fluorodeoxyglucose in the inguinal and both adnexal
areas as detected by [(18)F] fluorodeoxyglucose (FDG)
positron emission tomography (PET), then post-
operational pathological diagnosis confirmed low-grade
differentiation serous papilliferous adenocarcinoma of
both ovaries (size not known), and metastatic bilateral
inguinal lymph nodes, without any intraperitoneal or
lymphatic spread. Afterwards, Ang et al. [21] reported a
patient with left ovarian adenocarcinoma (9.0 × 6.4 cm)
presented with isolated metastasis to the right inguinal
lymph node, there were no other sites of involvement.
Thus, the case we reported was one of the few cases
which have complete clinicopathological informations in
existing literatures. However, different from Scholz’s and
Ang's case, in which large (10 × 5.5 cm) and (9.0 × 6.4
cm) tumor burden were found, our case demonstrated
relatively small tumor burden (5 cm in largest diameter),
disease was localized only within the right ovary, initially
presented with right SILN metastasis, without any evi-
dence of extensive intra-abdominal dissemination, and
retroperitoneal pelvic or paraaortic lymph nodes metas-
tasis. Therefore, this is the fourth case of ovarian carcin-
oma which presented with isolated SILN metastasis
reported in existing literatures.
Diagnosis and prognosis
Ovarian carcinoma usually presents with advanced stage
at their initial visit (FIGO Stage III and IV), with signs
and symptoms related to the diffused intraperitoneal dis-
ease [2]. However, the presence of asymptomatic isolated
SILN at the time of first visit frequently creates a diag-
nostic dilemma. This situation is unique not only in the
manner of disease presentation, but also in the time lag
from first seeking advice to evidence of intra-abdominal
malignancy [16].
In general, the common condition which might pre-
sented with palpable SILN enlargement include meta-
static disease or secondary inflammation [22]. Pathology
of tumors commonly metastasising to the inguinal
lymph nodes include breast cancer [23]; tumours arising
from the vulva and lower third of the vagina [24]; pelvic
malignancies [25]; malignant tumours of the skin, most
commonly primary malignant melanoma or squamous
cell carcinoma arising on the legs and trunk [14,24];
squamous cell carcinoma of the anal canal is also a com-
mon gastrointestinal tumour to metastasise to the in-
guinal lymph nodes [24]. Systematic infectious disease
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cers in the lower genital tract, Neisseria gonorrhoeae, can
also cause enlarged inguinal lymph node. Therefore, pre-
operative diagnosis of inguinal lymph node enlargement
always cause diagnostic dilemma and might involve gen-
eral practitioners, oncologists, dermatologists, and special-
ist nurses. However, antibiotics treatment for 4 to 6 week
is usually prescribed, followed by re-evaluation of the
lymphadenopathy [24]. Previous literatures showed that,
for patients with isolated inguinal metastasis of unknown
origin, laparoscopic surgery provided a minimally invasive
diagnostic approach of the abdominal and pelvic cavity, al-
though there controversy that a small tumor within the
ovary might be missed [22]. Imaging examination such as
TVUSG maybe helpful in detecting the earlier malignancy
in ovary. PET might has an appropriate role in the diagno-
sis of occult ovarian neoplasm, even in the absence of a
CA125 elevation [20]. The combination of FDG-PET/CT
was successfully used to identify ovarian cancer recur-
rence in an inguinal hernia sac [26]. Moreover, serum
levels of tumor markers such as CA125 can also assist to
determine the primary disease when the clinical presenta-
tion is atypical or confusing. However, in our case, we pro-
posed that, the management of a patient presenting with
inguinal enlargement of unknown origin should include
at least a detailed case history collection, complete
gynecological examination and some useful auxiliary diag-
nostic measures for any ovarian neoplasms. Sometimes,
even if no evident clinical signs and symptoms of a tumor
in the lower genital tract, isolated enlarged SILN should
also be paid enough attention for possible existence of an
occult malignant ovarian tumor. In other words, ovarian
cancer should be part of the differential diagnosis in
women with inguinal lymphadenopathy even without any
clinical evidence of intra-abdominal disease. Furthermore,
surgical excision or lymph node biopsy can be a indication
for inguinal lymphadenectomy, can provide better diag-
nostic and prognostic information.
The role of lymph node metastasis on survival in ovar-
ian cancer has been a matter of debate over the years [27].
Generally, lymph node metastasis is recognized as a par-
ameter of unfavorable prognosis. The prognosis of distant
metastasis in ovarian carcinoma is poor and the median
survival was only about 12 months [28]. While the oppos-
ite view suggested that, patients with ovarian carcinoma
which upstaged to stage III based solely on systematic
lymphadenectomy, have similar survival to stage I/II pa-
tients and superior survival to other stage III patients [29].
In fact, survival difference between node-positive-only
stage IIIC and intra-abdominal stage IIIC simply reflect
the prognostic impact of small versus large tumor size
[30]. “Node-positive-only” stage IIIC have a more favor-
able outcome than intra-abdominal stage IIIC and IIIA/B
in patients with epithelial ovarian cancer [31,32].The impact of SILN metastasis on the prognosis in
ovarian cancer is also in controversy. Some authors sug-
gested that patients with inguinal lymph node metastasis
as their first symptoms were associated with poor prog-
nosis, and can only survive for about three years [16,18].
While others argued that, in patients with recurrent epi-
thelial carcinoma, who presented as isolated lymph node
metastases (including inguinal nodal involvement),
complete optimal secondary cytoreductive surgery was
achievable in the majority of cases and were associated
with relatively favorable long-term survival outcome
[33,34]. Similar study also indicated that, for those suf-
fered with serous carcinoma of the ovary, fallopian tube,
or peritoneum, distant lymph node metastasis was an un-
common event (including inguinal nodal involvement),
however, this rare presentation does not adversely affect
survival, patients with minimal intra-peritoneal disease
and extra-abdominal lymph node metastases survive
longer than those with bulky peritoneal disease [35]. Ac-
cording to the new stage system, inguinal lymph node
metastasis was classified into FIGO Stage IVB ovarian
cancer [7]. While in the previous edition of stage system,
it was confusion about this, and inguinal lymph node
metastasis was usually put into Stage IIIc [9]. Therefore,
we supposed that, such stage difference might cause in-
consistency in data analysis on prognosis regarding in-
guinal lymph node metastasis.
The case reported here, was confirmed to be Stage
IVB ovarian cancer, and survive for five years after six
rounds of carboplatin plus paclitaxel systematic chemo-
therapy, with no evidence of recurrence. We consider it
that such patients presented only with distant lymphatic
metastasis, were in relatively better conditions and spe-
cific immune status, thus have better prognosis after
comprehensive treatment, as compared with bulky peri-
toneal disease. However, with the issue of new stage sys-
tem in the year of 2013 [7], large-scale and multicenter
analysis should be done to investigate clinical outcome
in patients with ovarian cancer confined to the ovary but
upstaged to stage IVB due to metastatic SILN, and pro-
vide more insight about potential differences in bio-
logical and clinical behavior of inguinal lymph node
versus intra-peritoneal metastasis. Furthermore, there is
no existing guideline on definitive management of pa-
tients with ovarian cancers metastasizing to isolated
SILN [22], efforts should be made to improve early diag-
nosis and finally prolong the survival of such patients.
We suggested that, such patients should be entered into
clinical trials of different treatment modalities in order
to develop optimal clinical guideline.
Routes and mechanisms of lymphatic metastasis
Generally, ovarian cancer has three routes for lymphatic
metastasis [36,37]. Firstly, lymphatic vessels mainly
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pelvic ligament towards the paraaortic and paracaval
lymph nodes. Thus, nodes running parallel to lymphatic
vessels are at highest risk of involvement. Once the pel-
vic and paraaortic lymph nodes have been involved,
lymphatic channels within the diaphragm and retroperi-
toneum will facilitate dissemination above the dia-
phragm. Less commonly, the second route follows the
subovarian plexus in the bilateral broad ligament to-
wards the obturator and pelvic iliac lymph nodes. The
third potential route follows the bilateral round ligament
of the uterus to the external iliac and deep inguinal
lymph nodes. We suggested that, in the absence of para-
aortic or pelvic lymphadenopathy which mainly depend
on the first and the second route as above mentioned,
the isolated SILN metastasis might attribute to the third
potential channel. Our case just provided support to
lymphatic dissemination via this potential channel,
through which ovarian cancer metastasize from the
round ligament to deep inguinal lymph node and finally
drained towards the SILN. However, the existence of
such a potential pathway has not been confirmed yet.
Moreover, hematogenous dissemination is also another
possible pathway for this special metastatic pattern, and
was reported to occur in approximately 2% to 3% of pa-
tients with primary ovarian carcinoma [10]. Theoretic-
ally, hematogenous route may account for dissemination
to any distant sites in ovarian cancer. Such as, early
extra-abdominal metastases [38], central nervous system
metastases [39], axillary lymph nodes [40], and breast
metastases [41,42], all support the model of spreading
through hematogenous route. Therefore, in summary,
we proposed that the event of isolated SILN metastasis
in ovarian cancer potentially involved two channels: via
deep inguinal lymphatic routes through round ligament
and/or hematogenous route.
In addition to study the routes of isolated SILN me-
tastasis in ovarian cancer, we should also explore its
underlying mechanisms. Current study revealed that ad-
vanced tumor stage, low-grade cell differentiation were
risk factors for the development of distant metastasis [28].
For instance, in our case with G3, low-grade cell differen-
tiation might contribute to one of important risk factors
for isolated SILN metastasis. In addition, mutation of p53
tumor suppressor gene was more likely to be associated
with distant lymph node metastases in ovarian cancer, in-
dicated that gene mutation and vascularization might also
contribute to distant metastasis in ovarian cancer [43].
Moreover, we speculated that, this special metastatic pat-
tern is probably the result of tumor biology and host-
tumor immunostatus. The special host immune state
within a specific time window perhaps plays a key role,
might kill some primary cancer cells but neglect distant
isolated lymph node metastasis. Nevertheless, there maybe a number of other unknown factors beyond our present
knowledge, such as unexplained hormones contributions.
Existing literatures have put more emphasis on pelvic and
paraaortic lymph nodes metastasis in ovarian cancer [36].
However, few studies had focused on the isolated SILN
metastasis, the exact molecular mechanisms and/or risk
factors of this special clinic metastatic pattern in ovarian
cancer still deserve further investigation.
Conclusions
Ovarian carcinoma isn’t a disease localized only within
the intraperitoneal cavity, isolated SILN metastasis can
occur and present as an initial symptom in rare case
with relative initial tumor origin stage, via potential
lymphatic and (or) hematogenous route under special
mechanisms which might include roles of immuno-
logical, pathological and hormonal factors. On the other
hand, it should be kept in mind that inguinal masses
might be the metastatic lesions of ovarian cancer. A
proper preoperative evaluation including gynecological
exam, cervicovaginal smear, CA 125 level and TVUSG
must be performed in such cases.
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